Immunogenicity and Safety of the 9-valent Human Papillomavirus (9vHPV) Vaccine in Japanese Boys and Girls (V503-066)

NCT04772534 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

314

Enrollment

INDUSTRY

Sponsor class

Conditions

Papillomavirus Infections

Interventions

BIOLOGICAL: 9vHPV vaccine

Sponsor

Merck Sharp & Dohme LLC